SCA
MRKR icon

Snowden Capital Advisors’s Marker Therapeutics MRKR Stock Holding History

Snowden Capital Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed – – 1665
2021
Q4 		$0 Buy
+100
New +$1.33K ﹤0.01% 2095

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Snowden Capital Advisors's MRKR Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 100 shares.

Snowden Capital Advisors first reported a position in MRKR in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 100 Marker Therapeutics shares in Q1 2022.
  • Snowden Capital Advisors first reported a position in Marker Therapeutics in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Marker Therapeutics position peaked at $0 in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.